CBD in Postmenopausal Women With Osteopenia

C

Canopy Growth

Status and phase

Terminated
Phase 1

Conditions

Osteopenia

Treatments

Drug: CBD
Other: Placebo

Study type

Interventional

Funder types

Industry
Other

Identifiers

NCT05317013
710022US1314

Details and patient eligibility

About

This is a Phase 1, double-blind, placebo-controlled, repeated-dose study to assess the safety, tolerability, and preliminary effects of CHI-554 in postmenopausal women ages 50-80 years who have osteopenia.

Enrollment

2 patients

Sex

Female

Ages

50 to 80 years old

Volunteers

No Healthy Volunteers

Inclusion criteria

  • Is a female aged 50-80 years, inclusive, at the time of screening.
  • Is postmenopausal, defined as > or = 12 months amenorrhoea.
  • Has osteopenia, defined as T score at lumbar spine or femoral neck or total femur of less than -1.0, but not less than or equal to -2.5, according to dual energy x-ray absorptiometry (DXA) completed at the Screening Visit or performed at NM Clinical Research & Osteoporosis Center up to 6 months prior to the Screening Visit.
  • Has been on a stable dose of 500 mg calcium daily for at least 7 days prior to Visit 1.
  • Has a body mass index between 18 and 35 kg/m2 (inclusive).
  • Is judged by the Investigator to be in generally good health at screening based on participants' medical history.
  • Must be adequately informed of the nature and risks of the study and give written informed consent prior to screening.

Exclusion criteria

  • Has a history of epilepsy, hepatitis, or human immunodeficiency virus.
  • Current or history of use of one or more prohibited medications (as described in Section 8.2.1.1).
  • Changes in the use of a prescription, over-the-counter (OTC), systemic or topical drug(s), herbal supplement(s), or vitamin(s) for the 4 weeks prior to the Screening Visit.
  • Evidence of clinically significant hepatic or renal impairment including alanine aminotransferase (ALT) or aspartate aminotransferase (AST) >1.5× the upper limit of normal (ULN), or bilirubin >2× ULN.
  • Has any clinically significant condition or abnormal finding at screening that would, in the opinion of the Investigator, preclude study participation or interfere with the evaluation of the study IP.
  • Has a history of a known significant allergic condition, significant drug-related hypersensitivity, or allergic reaction to any compound or chemical class related to cannabis, including phytocannabinoids and cannabinoid analogues, or excipients utilized within the IP (e.g., coconut; coconut oil; medium-chain triglycerides).
  • Has taken grapefruit products and/or Seville oranges within the 7 days prior to Visit 1.
  • Positive urine dipstick results for THC at the Screening Visit.
  • Has a history or current diagnosis of a significant psychiatric disorder, including alcohol or substance use disorder, that would, in the opinion of the Investigator, affect the subject's ability to comply with the study requirements.
  • Has participated in any investigational product or device study within 30 days prior to the Screening Visit, or is scheduled to participate in another investigational product or device study during the course of this study.
  • Demonstrates behavior indicating unreliability or inability to comply with the requirements of the protocol.
  • History of Osteoporosis diagnosis.

Trial design

Primary purpose

Supportive Care

Allocation

Randomized

Interventional model

Parallel Assignment

Masking

Triple Blind

2 participants in 3 patient groups, including a placebo group

Group A - 100 mg CBD
Experimental group
Description:
100 mg CBD per day
Treatment:
Drug: CBD
Group B - 300 mg CBD
Experimental group
Description:
300 mg CBD per day
Treatment:
Drug: CBD
Group C - Placebo
Placebo Comparator group
Description:
Placebo
Treatment:
Other: Placebo

Trial contacts and locations

1

Loading...

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location
© Copyright 2024 Veeva Systems